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Summary A range of new anthracyclines, structurally related to adriamycin (ADM), has been synthesised
and studied in vitro. Three compounds described in this paper (Ro 31-1215; Ro 31-1741; Ro 31-2035) are all
4-demethoxyanthracyclines. In the mouse mammary tumour cell line, EMT6/Ca/VJAC, using a 1 h drug
exposure followed by colony formation as the response endpoint, we found Ro 31-1215 and Ro 31-1741 to be
2-3 x and 4-7 x more potent then ADM, whilst Ro 31-2035 was 3-4 x less potent. For continuous drug
exposure and suppression of population growth as the endpoint, the potency of Ro 31-1741 was similar to
that of ADM, whereas that of Ro 31-1215 was 1.5-2 x higher and that of Ro 31-2035 was 10-20 x lower.
The potency ratios for continuous drug exposure of a human small cell lung cancer line were similar to those
for continuous exposure of EMT6. Variants of the two cell lines selected for resistance to ADM were also
studied. These variants also showed considerable resistance to Ro 31-1741 and Ro 31-2035 but much less
resistance to Ro 31-1215 (a 9-methyl derivative). A variant of EMT6 made resistant to Ro 31-1215 by
continuous growth in this drug was more resistant to ADM than it was to Ro 31-1215. Human cells resistant
to ADM contained 6 x less ADM after 24h exposure than did the parent line, whereas the ratio of drug
content for Ro 31-1215 was only 2.
The anthracycline antibiotic adriamycin
(doxorubicin, ADM) is one of the most useful
clinical cytotoxic drugs. It is used for the treatment
of a wide range of malignant diseases ranging from
the leukaemias to solid tumours such as lung and
ovarian carcinomas (Davis & Davis 1979). The
major dose-limiting toxicity of ADM is
cardiomyopathy which appears to be dependent
upon the total accumulated drug dose (Minow et
al., 1975). There is also a variety of evidence which
suggests that clinical effectiveness of ADM may be
limited by the development of cellular resistance to
the drug (Hubbard et al., 1978; Kaye & Merry,
1985). The mechanism of such resistance is
currently the subject of much ongoing laboratory
work and a variety of strategies for overcoming
resistance are being investigated (Tsuruo et al.,
1983; Skovsgaard et al., 1984).
Over the last 10 years a large number of
analogues of ADM have been produced with the
major objective of finding a drug which is less
cardiotoxic for a given amount of anti-tumour
effect (Naff et al., 1982). To date no drug has been
found to be clearly clinically superior to ADM.
More recently the additional objective of finding
anthracyclines which retain their effectiveness
against ADM-resistant cells has been encompassed.
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A new series of anthracyclines has now been
produced by Roche Products Ltd and in this paper
we describe our initial studies of the potency of
three of these agents against mouse and human
tumour cells in vitro. We have also investigated the
effectiveness of the agents against ADM-resistant
variants of our cell lines.
Materials and methods
Drugs
Adriamycin (ADM) was obtained from Sigma.
Novel anthracyclines, Ro 31-1215, Ro 31-1741 and
Ro 31-2035 were synthesised by Roche Products
Ltd. Their structures are shown in Figure 1. ADM,
Ro 31-1215 and Ro 31-1741 were dissolved in
distilled water at 500pgml-1 and aliquots stored at
-20°C. Ro 31-2035 was dissolved in propylene
glycol at 500pgml-1 and aliquots stored at
-20°C. Drugs were thawed and diluted in distilled
water immediately before use and added in a 50pl
volume to cells in 5ml of medium.
Cells
The mouse mammary tumour line EMT6/Ca/VJAC
was grown in Eagles MEM with 20% new-born
calf serum (Gibco Biocult) as a monolayer attached
to plastic. A variant line resistant to ADM was
obtained by inoculating a 75 cm2 tissue culture flask
with 106 cells in 0.2pgml-1 of ADM. After 10
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Figure 1 Structures of novel anthracyclines.
days a number of small areas of cell growth were
observed and these were allowed to develop with
medium change where necessary for 4 weeks. At
this time the cells were transferred to a new flask
and the concentration of ADM increased to
1.0pgml-1. After a further 4 weeks of passage in
1.0ygml-1 the variant line EMT6(AR) was defined
and a frozen stock established in liquid nitrogen
using medium containing 10% DMSO. A similar
method was used to obtain a variant line
EMT6(1215R) by alternate growth in the presence
or absence of Ro 31-1215 at final concentration of
0.1 Igml-1.
The human small cell lung cancer line NCI-H69
was originally supplied to us by Dr D. Carney of
the NCI/Navy Medical Oncology Branch. This line
grows as floating aggregates of cells in RPMI 1640
medium supplemented with 10% foetal calf serum
(Gibco Biocult). We have produced ADM resistant
variants of this line by a complicated regime of
growth in the presence and absence of ADM
(Twentyman et al., 1985) and these are designated
'H69/LX' (maintained in 0.1jIgml -1 ADM) and
'H69/LX4' (maintained in 0.4pgml-l ADM). The
parent line is designated 'H69/P'.
Two other human lung cancer cell lines, COR-
L47 (small cell) and COR-L23 (large cell) were used
in a limited number of experiments. The former
grows as floating aggregates and the latter as an
attached monolayer in RMPI 1640+10% foetal calf
serum (Baillie-Johnson et al., 1985).
Response experiments
Experiments to measure the drug response of
EMT6 cells (and resistant variants) were carried out
in one of three different ways.
(a) Acute Ih exposure with clonogenic assay Cells
were inocultated into a number of 25cm2 culture
flasks (Falcon) at 105 cells/flask and allowed to
grow for 2 days. During this period, ADM or
Ro 31-1215 resistant variants were grown in the
absence of drug. Cultures were then treated
for 1 h by addition of the test drug to the growth
medium and, at the end of this time, rinsed twice
and a single cell suspension obtained using trypsin
(0.075%) for 15min at 37°C. Cells were counted
using a haemocytometer, dilutions made, and
appropriate numbers of cells inoculated into 9cm
diameter plastic petri dishes (Sterlin) in 10ml of
medium. The dishes were incubated at 37°C in 8%
CO2 +92% air for 10 days at which time the dishes
were rinsed, fixed and stained with crystal violet.
Colonies containing more than 50 cells were then
enumerated. The plating efficiency of EMT6 was in
excess of 80% whilst that of EMT6(AR) was in the
range 30-50%.
(b) Continuous exposure with clonogenic assay
Bulk cultures of EMT6 or EMT6(AR) cells were
trypsinised and a number of 9cm petri dishes
incoluated with different numbers of cells. Drugs
were added to the dishes which were then incubated
for 10 days. At the end of this time, colonies were
stained and counted as in (a).
(c) Continuous exposure with cell count assay A
number of 5cm diameter petri dishes (Sterlin) were
inoculated with 5 x 104 EMT6, EMT6(AR) or
EMT6(1215R) cells taken from exponential phase
cultures. Drugs were added to the various dishes
and these were then incubated for 3 days. At the
end of this time the total number of phase-contrast
viable cells in each dish was determined using
trypsinisation and haemocytometer counting.
Experiments to measure the drug response of
NCI-H69 cells were carried out using a method
analogous to (c) above. From a growing culture of
cells, an aliquot was taken and a single cell
suspension prepared using trypsin (0.4%) and
versene (0.02%) for 15min. A suspension
containing single cells and small aggregates was
then prepared from the bulk of the suspension by
repeated pipetting. On the basis of the count
obtained on the formal single cell suspension, the
mechanical suspension was diluted and a number of
5cm diameter petri dishes were inoculated at
2 x 105 cell/dish. Drugs were then immediately
added. After 6 (H69/P or H69/LX cells) or 7 days
(H69/LX4) cells, a count of'pfiase contrast viable
cells in each dish was made using trypsin/versene
and a haemocytometer.
Experiments using small cell line COR-L47 were
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COR-L23 were also similar but with the use of
trypsin/versene to detach cells from monolayer on
plastic when setting up dishes initially and when
performing final counts.
Drug uptake
The content of ADM or Ro 31-1215 in NCI-H69
(P and LX4) grown in the continuous presence of
the drug was determined using our previously
described (Twentyman et al., 1985) adaptation of
the method of Schwartz (1973). Cells were grown
for 24 or 48h in the drugs and after rinsing they
were lysed, treated with silver nitrate and the drug
extracted using isoamyl alcohol. Fluorescence was
measured using a Perkin-Elmer MPF4 spectro-
fluorimeter with an excitation wavelength of 490nm
and an emission wavelength of 560nm (Ro 31-1215)
or 595nm (ADM).
Determination ofpartition coefficients
Partition coefficients were obtained by measuring
the fluorescence of drug solutions in Dulbecco 'A'
PBS, pH 7.4, before and after prolonged extraction
with n-octanol at 4°C. Duplicate 4ml samples of a
solution of each drug (5ugml-1 in PBS) were
extracted with an equal volume ofoctanol overnight,
in the dark, on a rotating wheel. Duplicate
control solutions were not extracted. After centri-
fugation the octanol layer was removed and the
fluorescence (F) of the aqueous layer determined
as described above for ADM and Ro 31-1215. For
Ro 31-1741 and Ro 31-2035, excitation wave-
lengths of 485 and 470nm respectively and an
emission wavelength of 565 nm were used. The
partition coefficient was given by:
F aqueous, extracted
F aqueous, control - F aqueous, extracted
In view of the pH used and the potential for
ionisation, the values obtained are, strictly speaking,
apparent partition coefficients or distribution
coefficients.
Results
Response ofEMT6 and EMT6(AR) cells - acute
(Ih) exposure
Survival data for EMT6 mouse tumour cells
exposed for 1 h to the various anthracyclines (assay
method (a)) are shown in Figure 2. From data such
as these, a value of ID80 (acute) is obtained as the
drug dose at which the best line fitted by eye to the
data crosses a surviving fraction of 0.2 (i.e. 80%
inhibition of colony growth). In almost all cases,
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Figure 2 Effect of anthracyclines on the survival of
EMT6 parent cells following a 1 h exposure. (0)
ADM; (V) Ro 31-1215; (U) Ro 31-1741; (-) Ro 31-
2035. Error bars shown on ADM points are 95%
confidence limits based on the total number of
colonies counted to determine survival. Error bars on
the other points are of similar dimensions.
the survival of the ADM-resistant variant
EMT6(AR) did not fall to this level at the highest
doses used. Values of ID80 from five experiments
are shown in Table I. In EMT6 cells, therefore,
using ID80 as an endpoint for comparison, Ro 31-
1215 and Ro 31-1741 are 2-3x and 4-7x more
potent than ADM respectively, whilst Ro 31-2035 is
3-4 x less potent (all for 1 h exposure). The
resistant variant shows considerable resistance to all
the analogues. We did not use higher drug doses in
the resistant cells because of solubility problems.
Response ofEMT6 and EMT6(AR) cells -
continuous exposure
A series of experiments was carried out in which
continuous exposure of EMT6 and EMT6(AR)
cells to the various drugs was studied. Results of
two experiments in which total cells per dish (i.e
assay method (c)) was used as the endpoint are
shown in Figure 3. In these experiments, the total
cells per dish in the control group increased from
5 x 104 to between 5 and 10 x 105 over 3 days.
From these data, values of ID80 (cont) (i.e. dose to
inhibit cell growth by 80%) are obtained and
shown in Table II. In these experiments the potency
of Ro 31-1741 was similar to that of ADM,
whereas that of Ro 31-1215 was 1.6-1.7x higher
A
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Table I ID80 (acute) values for EMT6 and EMT6(AR) cells exposed to anthracyclines for 1
hour
Cell ID80 ID80 drug ID80 drug in EMT6(AR)
Experiment Type Drug ,gml 1 ID80 ADM ID80 drug in EMT6
A EMT6 ADM 1.8
Ro 31-1741 0.46 0.26
Ro 31-2035 6.6 3.7
EMT6(AR) ADM >20.0 >11.0
Ro 31-1741 >4.0 >8.0
Ro 31-2035 58.0 8.8
B EMT6 ADM 0.71
Ro 31-1215 0.37 0.52
EMT6(AR) ADM >5.0 - >7.0
Ro 31-1215 >2.0 >5.0
C EMT6 ADM 1.6
Ro 31-1741 0.23 0.14
Ro 31-2035 4.6 2.9
EMT6(AR) ADM >20.0 > 12.0
Ro 31-1741 > 10.0 >43.0
Ro 31-2035 46.0 10.0
D EMT6 ADM 1.1
Ro 31-1215 0.32 0.29
EMT6(AR) ADM >5.0 >4.0
Ro 31-1215 >2.0 >6.0
E EMT6 ADM 1.0
Ro 31-1215 0.29 0.29 -
Ro 31-1741 0.19 0.19
Ro 31-2035 3.2 3.2
Table II ID80 (cont) values for EMT6 and EMT6(AR) cells exposed to anthracyclines
continuously
Cell ID80 ID80 drug ID80 drug in EMT6(AR)
Experiment type Drug pgml-l ID80 ADM ID80 drug in EMT6
A EMT6 ADM 0.09
Ro 31-1215 0.14 1.6
Ro 31-1741 0.068 0.76
Ro 31-2035 0.92 10.2
EMT6(AR) ADM 2.2 24.0
Ro 31-1215 1.2 8.6
Ro 31-1741 1.7 25.0
Ro 31-2035 14.5 16.0
B EMT6 ADM 0.042
Ro 31-1215 0.07 1.7
Ro31-1741 0.04 0.95
Ro 31-2035 0.84 20.0 -
EMT6(AR) ADM 1.0 24.0
Ro 31-1215 0.59 8.4
Ro 31-1741 1.1 28.0
Ro 31-2035 8.2 9.8NOVEL ANTHRACYCLINES AND CROSS-RESISTANCE 589
Drug dose (Gg ml-') comparison of the data in Tables I and II) was
0.01 0.1 1.0 10 around 20 for ADM and between 3 and 5 for the 1.0 -, >,other three agents.
*\\\+ '^s\., Experiments carried out using continuous drug
A' \ \expsoure of EMT6 and EMT6(AR) cells but with
ID80 colony formation as the endpoint (i.e. assay method
10l o-\ , (b)) gave very similar results to those described
above. The potencies of ADM, Ro 31-1215 and Ro
\ \T 31-1741 were rather similar, whilst that of Ro 31-
ADM 2035 was lower by 10-20 x. Additionally the
10-2 resistance factor for Ro 31-1215 was again
I ) 0.01 0.1 1.0 10 somewhat less than those for the other 3 agents.
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\ A Response ofEMT6(1215R) cells - continuous
exposure
-\ "\0 Experiments similar to those shown in Figure 3 and
using total cells per dish after 3 days as the end-
point (i.e. assay method (c)) were carried out to
determine the response of EMT6 and EMT6
1.0 10 100 (1215R) cells to both ADM and to Ro 31-1215.
The results from 2 experiments are shown in Figure
0\ °\ 4 and the ID80 values obtained from them are
A ",\ shown in Table III. It may be seen that despite the
t '\ o fact that Ro 31-1215 was the drug used to induce
resistance, the resistance factor for Ro 31-1215 was
considerably lower in both experiments than that
for ADM. i
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Figure 3 Effect of continuous incubation with
anthracyclines on the growth of EMT6 parent (closed
symbols) and EMT6(AR) (open symbols) cells. Two
independent experiments (indicated by circles and
triangles) are shown for each drug. Note that the
doses on the abscissa are 10x higher for Ro 31-2035
than for the other agents. Error bars shown on the
ADM data indicate 95% confidence limits based on
the total number of cells counted. Error bars on the
other points are of similar dimensions.
and that of Ro 31-2035 was 10-20 x lower. The
resistance factor (i.e. ratio of ID80s for resistant
and parent cells) for Ro 31-1741 was similar to that
for ADM, whilst that of Ro 31-1215 was 3 x lower.
The value for Ro 31-2035 was intermediate. The
ratio of ID80 (acute) to ID80 (cont) (based on a
Response ofNCI-H69 cells - continuous exposure
The relative effects of the 4 anthracyclines in
suppressing the growth of parent H69/P cells are
shown in Figure 5. In experiments such as this, the
number of cells in control dishes rose from 2 x 105
at the beginning of the experiment to around
2 x 106 at the end (day 6). ID80 values from a
number ofexperiments are shown in Table IV.
It may be seen that for parent (H69/P) cells, the
4 values of relative potency for Ro 31-1741 lie
between 0.39 and 0.89, whilst those for Ro 31-2035
lie between 5.7 and 11.4. There are 8 values for Ro
31-1215 ranging from 0.4 to 4.3 with a mean of 1.3.
The potency of Ro 31-1215 is therefore a little
lower than that of ADM and the potency of Ro 31-
1741 a little higher. That of Ro 31-2035 is
considerably less. These results are therefore in
reasonable agreement with those obtained using
continuous exposure in EMT6 cells.
The resistance factor of partially ADM resistant
(H69/LX) cells is somewhat lower for Ro 31-1741
and Ro 31-2035 than for ADM. These cells are not
resistant to Ro 31-1215. When, however, fully
ADM resistant (H69/LX4) cells are used, a
relatively small amount of resistance to Ro 31-1215
is seen (Figure 6 and Table IV). In 4 experiments,
however, the resistance factor of H69/LX4 cells to
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Figure 4 Effect of continuous incubation with ADM
(upper panel) or Ro 31-1215 (lower panel) on the
growth of EMT6 parent (closed symbols) or
EMT6(1215R) (open symbols) cells. Two independent
experiments (indicated by circles and triangles) are
shown for each drug. Error bars in the upper panel
are 95% confidence limits based on the total number
of cells counted. Error bars on the other points are of
similar dimensions.
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Figure 5 Effect of continuous incubation with
anthracyclines on the growth of NCI-H69 (parent)
human lung cancer cells. (-), ADM; (V) Ro 31-1215;
(0) Ro 31-1741; (-) Ro 31-2035. Confidence limits
on the points are of similar dimensions to those shown
in Figure 6.
Ro 31-1215 was always at least 10x less than the
factor for ADM.
Response ofother human cell lines
Studies on cells of the COR-L47 and COR-L23
lines exposed to continuous drugs gave similar
results in terms of relative potencies to those
obtained with NCI-H69 (data not shown).
Drug uptake studies
The results of experiments to measure the cellular
content of ADM or Ro 31-1215 during prolonged
incubation in 0.4 1gml-1 are shown in Table V. It
may be seen that whereas the ratio of drug content
for parent (H69/P) vs. ADM resistant (H69/LX4)
cells was around 6 for ADM, the ratio was only
around 2 for Ro 31-1215.
Table III ID80 values of EMT6(1215R) cells exposed continuously to ADM or
to Ro 31-1215
Cell ID80 ID80 drug in EMT6(1215R)
Experiment type Drug ggml-1 ID80 drug in EMT6
A EMT6 ADM 0.065
Ro 31-1215 0.079a
EMT6 ADM 0.80 12.3
(1215R) Ro 31-1215 0.38a 4.8
B EMT6 ADM 0.047
Ro 31-1215 0.072
EMT6 ADM 0.86 18.3
(1215R) Ro 31-1215 0.18 2.5
aThese values are ID70 (i.e. 70% reduction in cell number) as the curves did not
fall sufficiently to enable ID80 to be determined.
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Table IV ID80 (cont) values for NCI-H69 cells exposed continuously to anthracyclines
Cell
eriment typea Drug
A H69/P ADM
Ro 31-1741
Ro 31-2035
B H69/P ADM
Ro 31-1215
C H69/P ADM
Ro 31-1741
Ro 31-2035
H69/LX ADM
Ro 31-1741
Ro 31-2035
D H69/P ADM
Ro 31-1215
Ro 31-1741
Ro 31-2035
H69/LX ADM
Ro 31-1215
Ro 31-1741
Ro 31-2035
E H69/P ADM
Ro 31-1215
H69/LX ADM
Ro 31-1215
F H69/P ADM
Ro 31-1215
H69/LX4 ADM
Ro 31-1215
G H69/P ADM
Ro 31-1215
H69/LX4 ADM
Ro 31-1215
H H69/P ADM
Ro 31-1215
H69/LX4 ADM
Ro 31-1215
I H69/P ADM
Ro 31-1215
H69/LX ADM
Ro 31-1215
H69/LX4 ADM
Ro 31-1215
J H69/P ADM
Ro 31-1215
Ro 31-1741
Ro 31-2035
ID80
pgml-'
0.047
0.021
0.28
0.075
0.029
0.019
0.017
0.16
0.13
>0.4
0.63
0.028
0.075
0.011
0.32
0.17
0.055
0.037
1.4
0.075
0.047
0.20
0.056
0.013
0.012
1.1
0.048
0.0040
0.017
0.88
0.17
0.021
0.027
1.2
0.072
0.015
0.020
0.060
0.018
0.55
0.074
0.028
0.058
0.018
0.16
ID80 drug ID80 (LX or LX4 cells)
ID80 ADM ID80 (P cells)
0.45
6.0
0.4
0.89
8.4
2.7
0.39
11.4
0.62
0.92
4.3
1.3
1.4
6.8
>2.4
3.9
6.1
0.7
3.4
2.2
2.7
1.2
85.0
4.0
220.0
10.0
57.0
2.7
4.0
0.86
37.0
3.5
2.1
0.64
5.7
'H69/P are parent cells, H69/LX are partially ADM-resistant, H69/LX4 are fully ADM
resistant (see Materials and methods).
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Figure 6 Effect of continuous incubation with ADM
or Ro 31-1215 on the growth of NCI-H69 cells. Parent
(H69/P) cells: Response to ADM (0); Response to Ro
31-1215 (0). Partially ADM-resistant (H69/LX) cells:
Response to ADM (A); Response to Ro 31-1215 (A).
Fully ADM-resistant (H69/LX4) cells: Response to
ADM (U); Response to Ro 31-1215 (CI). Error bars
shown on some points indicate 95% confidence limits
based on the total number of cells counted. Errors on
other points are of similar dimensions.
Table V Drugs content of NCI-H69 cells after 24h
incubation in drug-containing medium (0.4pgml-1)
Drug content
Experiment Drug Cellsa (pg10'- cells)b
A ADM H69/P 3.89
H69/LX4 0.60
B Ro 31-1215 H69/P 2.82
H69/LX4 1.54
C ADM H69/P 6.16
H69/LX4 0.97
Ro 31-1215 H69/P 5.51
H69/LX4 2.76
'H69/P are parent cells, H69/LX4 are fully ADM-
resistant (see Materials and methods); bThose values are
based on the numbers of cells initially inoculated in the
dishes. Counts of phase-contrast viable cells recoverable
from the various dishes after 24h gave values within 20%
of the initial inoculum.
Partition coefficient
The experiments to measure the apparent partition
coefficients between n-octanol and phosphate buffer
(pH =7.4) for ADM and the 3 analogues were
carried out wice with duplicate extractions being
measured in each experiment. The partition
coefficient values obtained were ADM=0.40, 0.53;
Ro 31-1215=20.5, 35.4; Ro 31-1741=9.6, 16.3;
Ro 31-2035=40.7, >100. Thus the order of
lipophilicity was Ro 31-2035>Ro 31-1215>Ro 31-
1741 >ADM.
Discussion
The three novel anthracyclines described in this
paper are members of a larger group of compounds
recently produced by total synthesis. They are all 4-
demethoxyanthracyclines. The particular interest in
4-demethoxy compounds is based on the analysis
by Naff et al. (1982) of NCI screening data of over
400 anthracyclines. The overall activity of
daunomycin analogues was found to increase as the
4-position substitutent was changed from OCH3 to
OH to H and, in the ADM series, the activity of 4-
demethoxyadriamycin was greater than that of
ADM. The three compounds which we have
studied were selected from a large group on the
basis of preliminary in vivo screening data carried
out in a mouse L1210 model system and a mouse
mammary tumour (Hartmann et al., 1985). The
compound Ro 31-2035 is also believed to be
considerably less cardiotoxic than ADM
(Hartmann, personal communication).
Our data indicate that the relative potencies of
the agents in our in vitro tesing systems depend
upon the method of testing. Although in all cases,
Ro 31-2035 was found to be less potent than
ADM, the factor was 3 x for a 1 h exposure of
EMT6 cells and 6-20x for various experiments
using continuous exposure of either EMT6 or NCI-
H69 cells. Similarly, whereas Ro 31-1215 and Ro
31-1741 were 2-4 x and 4-7 x respectively more
potent than ADM for 1 h exposure in EMT6, the
factors for continuous exposure indicate that Ro
31-1215 is a little less potent than ADM whilst Ro
31-1741 is 1-2 x more potent. These differences
may be due to the widely different lipophilicities of
the different compounds. A comparison of the
cellular pharmacokinetics of ADM (partition
coefficient, PC=0.5) and aclacinomycin A
(PC= 21.8) (Zenebergh et al., 1982) indicated that
the latter compound is taken up and released more
rapidly by cells. The distribution of the 2 drugs
between cellular compartments after 5h of
incubation was quite different. Hence it may be
expected that the ratio of effects of a I h exposure
(when equilibrium distribution of some drugs will
not have been achieved) and a continuous exposure
may well be lipophilicity dependent.
The relevance of different in vitro exposure times
to the clinical use of anthracyclines is very difficult
to assess. Following ADM administration, there are
3 phases of plasma clearance with half-lives of
n t A T _ I
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5min, 0.8h and 19h (Robert et al., 1982). The
relative contributions of these various phases to
overall tumour response is not established, although
there appeared to be a correlation between tumour
response and a parameter related to the early phase
of plasma clearance (Robert et al., 1982). Recent in
vitro concentration x time studies using NCI-H69
cells (Twentyman & Fox, in preparation) indicate
that the concentration x time of each phase of the
patient plasma curve lies within the range able to
cause significant effects on cell growth. At the
present time, therefore, determinations of relative
potency based on in vitro testing must be regarded as
general indicators rather than precise quantitative
predictions of likely in vivo effects.
Our finding that Ro 31-1215 shows little loss of
activity in ADM-resistant cells is of considerable
potential importance. It is widely accepted that the
development of resistance to ADM is a significant
clinical problem. Most anthracyclines that have
been studied have been found to lose activity in
ADM-resistant cells. A mouse fibrosarcoma line
resistant to ADM was also resistant to
daunorubicin and to mAMSA (Giavazzi et al.,
1983) and similar conclusions were reached by
Schabel et al. (1983) using an ADM-resistant
subline of P388 leukaemia. For aclacinomycin A
(ACL), however, little loss of activity appears to
occur in ADM-resistant lines (Tsuruo et al., 1983;
Hill et al., 1985; Twentyman et al., 1985). In
addition, retention of activity in an ADM-resistant
line of L5178Y lymphoma was seen for 4
anthracyclines (including 4'deoxyadriamycin) by
Hill et al. (1985). However, the ADM-resistance
factor for this line was low. Our own studies for
4'deoxyadriamycin (Twentyman et al., 1985) show
as great a loss of activity as that seen for ADM.
The data presented in this paper for Ro 31-1215
indicate that it is of similar efficiency to ACL in
overcoming ADM-resistance (Twentyman et al.,
1985). The subline H69/LX of small cell lung
cancer line NCI-H69, is resistant to ADM by a
factor which varies between 4 and 30 in individual
experiments, but is not resistant to either ACL or
Ro 31-1215. The subline H69/LX4 (resistance
factor for ADM=40-200) is resistant to ACL and
Ro 31-1215 by 2-4 x . We therefore believe that Ro
31-1215 is as good a candidate as ACL for an
anthracycline with retained activity in ADM-
resistant cells. Our studies on cellular content of
ADM and Ro 31-1215 during prolonged incubation
indicate that cellular pharmacokinetic differences
may be involved in these relative resistance
characteristics. It is interesting that EMT6 cells
made resistant to Ro 31-1215 by growth in the drug
show a higher resistance factor for ADM than they
do for Ro 31-1215 itself. This may indicate that the
mechanism of resistance in these cells is the same as
that in cells made resistant by growth in ADM.
Additional studies using compounds synthesised by
Roche Products (Scott et al., 1985; 1986) have
determined that several 9-methyl and 9-ethyl
substituted 4-demethoxy anthracyclines also show
retention of activity in ADM-resistant cells. This
may indicate the prime importance of a 9-alkyl
substitution in conferring such a property. The fact
that ACL also has a 9-alkyl group would support
this proposition.
We are currently carying out detailed studies in
animal systems designed to compare directly the 3
novel anthracyclines reported in this paper with
ADM in terms of therapeutic efficiency. Studies
into the relative cardiotoxicity of the compounds
are also in progress.
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